OrbiMed’s $15 M Pre‑Funded Warrant Buy at Shattuck Labs Signals Bullish Confidence Ahead of SL‑325 Phase 1 Data

Insider Activity Spotlight: OrbiMed Advisors’ Strategic Moves at Shattuck Labs

Shattuck Labs’ share price is hovering around $4.27, and the latest Form 4 filed on June 8, 2026 shows that OrbiMed Advisors LLC – through its GP and Master Fund structures – has executed a sizable buy of pre‑funded warrants. The transaction, worth 15 million pre‑funded warrants, gives OrbiMed the right to purchase up to 12 million additional shares at the same $0.8676 price set in the August 2025 private placement. With the company’s 52‑week high at $8.33 and a recent 39 % year‑to‑date gain, this move signals confidence in the pipeline, especially as the Phase 1 data for SL‑325 will be disclosed shortly.

What It Means for Investors

A pre‑funded warrant is a lower‑cost entry point: investors lock in a future purchase price while the company raises capital immediately. For shareholders, the buy adds liquidity pressure on the share price if the warrants are exercised, but it also suggests that a savvy institutional player is bullish enough to back the company at a discounted valuation. The recent social‑media buzz (134 % above average) and positive sentiment (+57) amplify the perception that the market is watching closely. If the upcoming webcast confirms robust safety and efficacy signals, the warrants could be exercised in the near term, potentially diluting the current 300‑plus‑million share base and pushing the price higher.

OrbiMed Advisors’ Historical Playbook

OrbiMed has been a recurring name in Shattuck’s insider filings. Since August 2025, the firm has purchased:

• 5.25 million common shares (≈ $4.5 M at the placement price)
• 10.1 million pre‑funded warrants (≈ $8.8 M)
• 3.07 million common warrants (≈ $2.7 M)
• 15.36 million common warrants (≈ $13.3 M)

These purchases collectively amount to roughly $30 million in direct capital commitments. The pattern shows a preference for warrants, implying a strategy that balances immediate funding with future upside potential. By holding the warrants and retaining the option to exercise, OrbiMed preserves flexibility while signaling confidence in Shattuck’s long‑term trajectory.

Board Representation and Governance Impact

The filing notes that Mona Ashiya, an OrbiMed representative, serves on Shattuck’s board. Her presence gives OrbiMed a voice in strategic decisions, including the timing of future financing rounds and pipeline prioritization. This dual role of investor and board member may accelerate decision‑making, potentially benefiting shareholders if the company can secure additional funding without significant dilution.

Outlook for the Clinical‑Stage Company

Shattuck’s Phase 1 results will be a critical catalyst. A positive safety and pharmacodynamic profile for SL‑325 could trigger warrant exercise, diluting the share base but potentially increasing the share price. The company’s market cap of ~$295 M and a P/E of -7.46 reflect a typical biotech risk profile: high growth potential but current losses. The recent insider activity—especially OrbiMed’s sizable warrant purchase—suggests that the institutional sector remains optimistic, which may attract additional capital or strategic partnerships. Investors should watch the webcast and any subsequent regulatory filings for clues on whether the warrants will be exercised and how the company plans to leverage its pipeline for future commercialization.

In summary, OrbiMed Advisors’ latest purchase of pre‑funded warrants at Shattuck Labs signals confidence ahead of key clinical data. For investors, this activity implies potential dilution but also a strong institutional endorsement that could drive the stock higher if the upcoming Phase 1 results are favorable.